| _version_ |
1860797479365115904
|
| building |
INTELEK Repository
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| date |
2016-03-22 15:45:51
|
| format |
Restricted Document
|
| id |
12898
|
| institution |
UniSZA
|
| internalnotes |
Anyama N, Sseguya S, Okwera A, El-Naggar WA, Mpagi F, Owino E. The challenge of re-treatment pulmonary tuberculosis at two teaching and referral hospitals in Uganda. Afr Health Sci, 2007; 7(3): 136- 142. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2269710/pdf/AFHS0703-0136.pdf [Accessed 10 October 2015]. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A, & Tuberculosis Trials Consortium. Relapse Associated with Active Disease Caused by Beijing Strain of Mycobacterium tuberculosis. Emerg Infect Dis, 2009; 15(7): 1061-1067. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744226/pdf/08-1253_ finalR.pdf [Accessed 10 October 2015]. Chaisson RE, Churchyard GJ. Recurrent tuberculosis: relapse, reinfection, and HIV. The J Infect Dis, 2010; 201(5):653-5. doi: 10.1086/650531. Available at: http://jid.oxfordjournals.org/content/ 201/5/653.full.pdf+html [Accessed 10 October 2015]. Chandrasekaan V, Gopi PG, Santha T, Subramani R, Narayanan P. Status of re-registered patients for TB treatment under DOTS programme. Indian J Tuberc, 2006; 54(1):12-6. Available at: http://medind.nic.in/ibr/t07/i1/ibrt07i1p12.pdf [Accessed 10 October 2015]. Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, Byrne G, Stone C, Niemann S, Rüsch-Gerdes S, Blok L, Doshetov D. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med, 2006; 3(10): 384. Available at: http://www.plosmedicine.org/article/fetchObject.action? uri=info%3Adoi%2F10.1371%2Fjournal.pmed.0030384&representation= PDF [Accessed 10 October 2015]. Dale JW, Nor RM, Ramayah S, Tang TH, Zainuddin ZF. Molecular epidemiology of tuberculosis in Malaysia. J Clin Microb, 1999; 37(5): 1265-1268. Available at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC84747/pdf/jm001265.pdf [Accessed 10 October 2015]. Daniel TM. The history of tuberculosis. Respiratory Medicine, 2006; 100: 1862–1870. Available at: http://www.sciencedirect.com/ science/article/pii/S095461110600401X [Accessed 10 October 2015]. Dholakia Y, Danani U, Desai C. Relapse following directly observed therapy short course (DOTS) a following up study. Indian J Tuberc, 2000; 47(4): 233-236. Available at: http://medind.nic.in/ ibr/t00/i4/ibrt00i4p233.pdf Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in Persons Treated for Drug-Susceptible Tuberculosis in a Population with HighCoinfection with Human Immunodeficiency Virus in New York City. Clin Infect Dis, 2001; 33(10): 1762-1769. Available at: http://cid.oxfordjournals.org/content/33/10/1762.full.pdf+html [Accessed 10 October 2015]. East African-British Medical Research Council (EABMRC). Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African-British Medical Research Council Study. Am Rev Respir Dis, 1976; 114(3): 471- 475. East African-British Medical Research Councils (EABMRC). Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet, 1972; 1(7816): 1331-1338. East African-British Medical Research Councils (EABMRC). Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis, 1977; 116(1): 3-8. El Sahly HM, Wright JA, Soini H, Bui TT, Williams-Bouyer N, Escalante P, Musser JM, Graviss EA. Recurrent TB in Houston, Texas: a population-based study. Int J Tuberc Lung Dis, 2004; 8(3): 333-340. Available at: http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/ 80320556.1/iuatld/ijtld/2004/00000008/00000003/art00010/79007A5A32 1EC922141993024954BB684D221A666A.pdf?link=http://www.ingentac onnect.com/error/delivery&format=pdf [Accessed 11 October 2015]. Fine PEM, Small PM. Exogenous reinfection in tuberculosis. New Engl J Med. 1999; 341:1226-1227. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 2008; 22(18): 2527-2533. Available at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2603140/pdf/nihms80165.pdf [Accessed 11 October 2015]. Iseman M. Tuberculosis History [Internet]. National Jewish Health, 2013. Available at: http://www.nationaljewish.org /healthinfo/ conditions/tb/history[Accessed 11 October 2015]. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ, Tuberculosis Trials Consortium. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med, 2004; 170(12): 1360- 1366. Available at: http://www.atsjournals.org/doi/pdf/10.1164/rccm.2004 08-1081OC [Accessed 11 October 2015]. Kopanoff DE, Snider Jr DE, Johnson M. Recurrent TB: Why do patients develop disease again? USA public health servivces cooperative survey. Am J Public Health, 1998; 78(1): 30-33. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1349202/pdf/amjph00240- 0032.pdf [Accessed 11 October 2015]. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clinc Infect Dis, 2003; 37(1): 101-112. Available at: http://cid.oxfordjournals.org/ content/37/1/101.full.pdf+html [Accessed 11 October 2015]. Lambert ML, Hasker E, Deun AV, Roberfroid D, Boelaert M, Stuyft PV. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis, 2003; 3:282–287. Available at: http://ac.elscdn.com/S1473309903006078/1-s2.0-S1473309903006078-main.pdf?_ tid=c6d290d4-8f36-11e4-b322-00000aab0f6b&acdnat= 1419842795_943364d4cd922efcf5e358c81eb4a2c [Accessed 11 October 2015]. Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis, 200; 4(5): 455-462. Available at: http://docstore.ingenta.com/cgibin/ds_deliver/1/u/d/ISIS/80320579.1/iuatld/ijtld/2000/00000004/0000000 5/art00011/8621844D50C6E18E1419930558F6CACB7FD18BC7C5.pdf? link=http://www.ingentaconnect.com/error/delivery&format=pdf [Accessed 11 October 2015]. Millet JP, Shaw E, Orcau A, ´Casals M, Miro JM, Cayla JA, the Barcelona Tuberculosis Recurrence Working Group. Tuberculosis Recurrence after Completion Treatment in a European City: Reinfection or Relapse? PLoS ONE, 2013; 8(6): e64898. doi:10.1371/ journal.pone. 0064898. Available at: http://www.plosone.org/article/fetchObject.action? uri=info%3Adoi%2F10.1371%2Fjournal.pone.0064898&representation=P DF [Accessed 12 October 2015]. Ministry of Health. Clinical Practice Gudielines. Management of Tuberculosis. 3rd Edition. Malaysia Health Technology Assessment Section (MaHTAS), Medical Development Division, Ministry of Health Malaysia, Level 4, Block E1, Precinct 1, Federal Government Administrative Centre 62590, Putrajaya, Malaysia. 2012. Available at: http://www.moh.gov.my/attachments/8612.pdf [Accessed 12 October 2015]. Ministry of Health. Health Facts 2009. Available at: http://vlib.moh.gov.my/cms/documentstorage/com.tms.cms.document.Doc ument_4add873f-c0a81049-13ce5ad0-9b5bdb32/2009.pdf Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis, 2007; 11(8): 828-837. Available at: http://www.researchgate.net/publication/6133784_Recurrent_tuberculosis _and_its_risk_factors_adequately_treated_patients_are_still_at_high_risk [Accessed 12 October 2015]. Shen G, Xue Z, Shen X, Sun B, Gui X, Shen M, Mei J, Gao Q. Recurrent tuberculosis and exogenous reinfection, Shanghai, China. Emerg Infect Dis, 2006; 2(11): 1776-1778. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372325/pdf/05-1207.pdf Sun YJ, Lee ASG, Wong SY, Paton NI. Association of Mycobacterium tuberculosis Beijing genotype with tuberculosis relapse in Singapore. Epidemiol Infect, 2006; 134(2): 329-332. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870406/pdf/S095026880 500525Xa.pdf [Accessed 12 October 2015]. Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, Sadacharam K, Narayanan PR. Predictors of relapse among pulmonary TB in patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis, 2005; 9(5):556-561. Available at: http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/80321756.1/ iuatld/ijtld/2005/00000009/00000005/art00016/52B571555964205214199 3987407302C35E9E08700.pdf?link=http://www.ingentaconnect.com/erro r/delivery&format=pdf [Accessed 12 October 2015]. Tuberculosis Research Centre (TRC). A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre. Int J Tuberc Lung Dis, 1997; 1(6): 509-517. Available at: http://docstore.ingenta.com/cgibin/ds_deliver/1/u/d/ISIS/80321827.1/iuatld/ijtld/1997/00000001/0000000 6/art00007/7754C218C7B4F864141994019730BB7669EB7F1838.pdf?lin k=http://www.ingentaconnect.com/error/delivery&format=pdf [Accessed 12 October 2015]. Tuberculosis Research Centre (TRC). Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle, 1983; 64(2): 73-91. Available at: http://ac.elscdn.com/0041387983900326/1-s2.0-0041387983900326- main.pdf?_tid=9a08b35a-901a-11e4-a802- 00000aab0f27&acdnat=1419940645_afb8443dddffe68a1db9041568483c5 8 [Accessed 12 October 2015]. Uddin SN, Hossain SJ, Huda MN, Rahman MH, Ali ME. Consequence on Treatment of TB Patients Affected by HIV/AIDS A Conceptual Research. Am J Infect Dis, 2006; 2 (4): 210-218. Available at: http://www.researchgate.net/publication/26460063_Consequence_on_Trea tment_of_TB_Patients_Affected_by_HIVAIDS_A_Conceptual_Research [Accessed 12 October 2015]. Van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Eng J Med, 1999; 341: 1174–1179 Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. Rate of Reinfection Tuberculosis after Successful Treatment Is Higher than Rate of New Tuberculosis. Am J Res Crit Care Med, 2005; 171(12): 1430- 1435. Available at: http://www.atsjournals.org/doi/pdf/10.1164/ rccm.200409-1200OC [Accessed 12 October 2015]. Vijay S, Kumar P, Chauhan LS, Vollepore BH, Kizhakkethil UP, Rao SG. Risk factors Associated with Default among New Smear Positive TB Patients Treated Under DOTS in India. PLoS One, 2010; 5(4):e10043. Available at: http://www.plosone.org/article/ fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.001004 3&representation=PDF World Health Organization. Global tuberculosis control. 2010. Available at: http://reliefweb.int/sites/reliefweb.int/files/resources/ F530290AD0279399C12577D8003E9D65-Full_Report.pdf [Accessed 12 October 2015]. World Health Organization. Malaysia TB country profile. 2013. Available at: https://extranet.who.int/sree/Reports?op=Replet&name=/ WHO_HQ_Reports/G2/PROD/EXT/TBCountryProfile&ISO2=my&outty pe=pdf [Accessed 12 October 2015]. World Health Organization. Media Centre. WHO launches new stop TB strategy to fight the global tuberculosis epidemic. 2006. Available at: http://www.who.int/mediacentre/news/releases/2006/pr12/en/ [Accessed 12 October 2015]. Yamagishi F, Toyota M. Research and control of relapse tuberculosis cases. Kekkaku (Tuberculosis), 2009; 84(12): 767-768.
|
| originalfilename |
7205-01-FH02-FP-16-05544.jpg
|
| person |
norman
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12898
|
| spelling |
12898 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12898 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal image/jpeg inches 96 96 norman 43 43 1419 764 2016-03-22 15:45:51 1419x764 7205-01-FH02-FP-16-05544.jpg UniSZA Private Access The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia Journal of Applied Pharmaceutical Science This study has the intention to determine the median time to develop recurrent tuberculosis [TB] in TB patients attending the Chest Clinic at Hospital Raja Perempuan Zainab II [HRPZ II], Kelantan, Malaysia. Records of 114 recurrent TB patients from 1/1/2003-31/12/2009 were analyzed. Kaplan-Meier analysis was used to examine the median time for recurrence of TB. The overall median time to develop TB recurrence in registered TB recurrent patients was six months [95%CI: 4.58, 7.42] after the previous episode. It was found that recipients of Streptomycin (S), Isoniazid (H) and Rifampicin (R) twice weekly (S2H2R2) drug regimen [p=0.026] or daily HR drug regimen [p=0.049] during the continuation phase took a longer duration to develop recurrent TB than nonrecipients of these medicines by Kaplan-Meier analysis. Moreover, there also existed a significant time difference [P = 0.006] between the defaulters and non-defaulters of treatment to develop recurrent TB. Patients should take the complete course of therapy, to reduce recurrent TB infection. The drug regimens must contain the two most potent first line drugs Isoniazid [H] and Rifampicin [R] during the continuation phase. 6 2 Open Science Publishers LLP Inc. Open Science Publishers LLP Inc. 097-103 Anyama N, Sseguya S, Okwera A, El-Naggar WA, Mpagi F, Owino E. The challenge of re-treatment pulmonary tuberculosis at two teaching and referral hospitals in Uganda. Afr Health Sci, 2007; 7(3): 136- 142. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2269710/pdf/AFHS0703-0136.pdf [Accessed 10 October 2015]. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A, & Tuberculosis Trials Consortium. Relapse Associated with Active Disease Caused by Beijing Strain of Mycobacterium tuberculosis. Emerg Infect Dis, 2009; 15(7): 1061-1067. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744226/pdf/08-1253_ finalR.pdf [Accessed 10 October 2015]. Chaisson RE, Churchyard GJ. Recurrent tuberculosis: relapse, reinfection, and HIV. The J Infect Dis, 2010; 201(5):653-5. doi: 10.1086/650531. Available at: http://jid.oxfordjournals.org/content/ 201/5/653.full.pdf+html [Accessed 10 October 2015]. Chandrasekaan V, Gopi PG, Santha T, Subramani R, Narayanan P. Status of re-registered patients for TB treatment under DOTS programme. Indian J Tuberc, 2006; 54(1):12-6. Available at: http://medind.nic.in/ibr/t07/i1/ibrt07i1p12.pdf [Accessed 10 October 2015]. Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, Byrne G, Stone C, Niemann S, Rüsch-Gerdes S, Blok L, Doshetov D. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med, 2006; 3(10): 384. Available at: http://www.plosmedicine.org/article/fetchObject.action? uri=info%3Adoi%2F10.1371%2Fjournal.pmed.0030384&representation= PDF [Accessed 10 October 2015]. Dale JW, Nor RM, Ramayah S, Tang TH, Zainuddin ZF. Molecular epidemiology of tuberculosis in Malaysia. J Clin Microb, 1999; 37(5): 1265-1268. Available at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC84747/pdf/jm001265.pdf [Accessed 10 October 2015]. Daniel TM. The history of tuberculosis. Respiratory Medicine, 2006; 100: 1862–1870. Available at: http://www.sciencedirect.com/ science/article/pii/S095461110600401X [Accessed 10 October 2015]. Dholakia Y, Danani U, Desai C. Relapse following directly observed therapy short course (DOTS) a following up study. Indian J Tuberc, 2000; 47(4): 233-236. Available at: http://medind.nic.in/ ibr/t00/i4/ibrt00i4p233.pdf Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in Persons Treated for Drug-Susceptible Tuberculosis in a Population with HighCoinfection with Human Immunodeficiency Virus in New York City. Clin Infect Dis, 2001; 33(10): 1762-1769. Available at: http://cid.oxfordjournals.org/content/33/10/1762.full.pdf+html [Accessed 10 October 2015]. East African-British Medical Research Council (EABMRC). Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African-British Medical Research Council Study. Am Rev Respir Dis, 1976; 114(3): 471- 475. East African-British Medical Research Councils (EABMRC). Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet, 1972; 1(7816): 1331-1338. East African-British Medical Research Councils (EABMRC). Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis, 1977; 116(1): 3-8. El Sahly HM, Wright JA, Soini H, Bui TT, Williams-Bouyer N, Escalante P, Musser JM, Graviss EA. Recurrent TB in Houston, Texas: a population-based study. Int J Tuberc Lung Dis, 2004; 8(3): 333-340. Available at: http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/ 80320556.1/iuatld/ijtld/2004/00000008/00000003/art00010/79007A5A32 1EC922141993024954BB684D221A666A.pdf?link=http://www.ingentac onnect.com/error/delivery&format=pdf [Accessed 11 October 2015]. Fine PEM, Small PM. Exogenous reinfection in tuberculosis. New Engl J Med. 1999; 341:1226-1227. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 2008; 22(18): 2527-2533. Available at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2603140/pdf/nihms80165.pdf [Accessed 11 October 2015]. Iseman M. Tuberculosis History [Internet]. National Jewish Health, 2013. Available at: http://www.nationaljewish.org /healthinfo/ conditions/tb/history[Accessed 11 October 2015]. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ, Tuberculosis Trials Consortium. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med, 2004; 170(12): 1360- 1366. Available at: http://www.atsjournals.org/doi/pdf/10.1164/rccm.2004 08-1081OC [Accessed 11 October 2015]. Kopanoff DE, Snider Jr DE, Johnson M. Recurrent TB: Why do patients develop disease again? USA public health servivces cooperative survey. Am J Public Health, 1998; 78(1): 30-33. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1349202/pdf/amjph00240- 0032.pdf [Accessed 11 October 2015]. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clinc Infect Dis, 2003; 37(1): 101-112. Available at: http://cid.oxfordjournals.org/ content/37/1/101.full.pdf+html [Accessed 11 October 2015]. Lambert ML, Hasker E, Deun AV, Roberfroid D, Boelaert M, Stuyft PV. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis, 2003; 3:282–287. Available at: http://ac.elscdn.com/S1473309903006078/1-s2.0-S1473309903006078-main.pdf?_ tid=c6d290d4-8f36-11e4-b322-00000aab0f6b&acdnat= 1419842795_943364d4cd922efcf5e358c81eb4a2c [Accessed 11 October 2015]. Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis, 200; 4(5): 455-462. Available at: http://docstore.ingenta.com/cgibin/ds_deliver/1/u/d/ISIS/80320579.1/iuatld/ijtld/2000/00000004/0000000 5/art00011/8621844D50C6E18E1419930558F6CACB7FD18BC7C5.pdf? link=http://www.ingentaconnect.com/error/delivery&format=pdf [Accessed 11 October 2015]. Millet JP, Shaw E, Orcau A, ´Casals M, Miro JM, Cayla JA, the Barcelona Tuberculosis Recurrence Working Group. Tuberculosis Recurrence after Completion Treatment in a European City: Reinfection or Relapse? PLoS ONE, 2013; 8(6): e64898. doi:10.1371/ journal.pone. 0064898. Available at: http://www.plosone.org/article/fetchObject.action? uri=info%3Adoi%2F10.1371%2Fjournal.pone.0064898&representation=P DF [Accessed 12 October 2015]. Ministry of Health. Clinical Practice Gudielines. Management of Tuberculosis. 3rd Edition. Malaysia Health Technology Assessment Section (MaHTAS), Medical Development Division, Ministry of Health Malaysia, Level 4, Block E1, Precinct 1, Federal Government Administrative Centre 62590, Putrajaya, Malaysia. 2012. Available at: http://www.moh.gov.my/attachments/8612.pdf [Accessed 12 October 2015]. Ministry of Health. Health Facts 2009. Available at: http://vlib.moh.gov.my/cms/documentstorage/com.tms.cms.document.Doc ument_4add873f-c0a81049-13ce5ad0-9b5bdb32/2009.pdf Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis, 2007; 11(8): 828-837. Available at: http://www.researchgate.net/publication/6133784_Recurrent_tuberculosis _and_its_risk_factors_adequately_treated_patients_are_still_at_high_risk [Accessed 12 October 2015]. Shen G, Xue Z, Shen X, Sun B, Gui X, Shen M, Mei J, Gao Q. Recurrent tuberculosis and exogenous reinfection, Shanghai, China. Emerg Infect Dis, 2006; 2(11): 1776-1778. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372325/pdf/05-1207.pdf Sun YJ, Lee ASG, Wong SY, Paton NI. Association of Mycobacterium tuberculosis Beijing genotype with tuberculosis relapse in Singapore. Epidemiol Infect, 2006; 134(2): 329-332. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870406/pdf/S095026880 500525Xa.pdf [Accessed 12 October 2015]. Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, Sadacharam K, Narayanan PR. Predictors of relapse among pulmonary TB in patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis, 2005; 9(5):556-561. Available at: http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/80321756.1/ iuatld/ijtld/2005/00000009/00000005/art00016/52B571555964205214199 3987407302C35E9E08700.pdf?link=http://www.ingentaconnect.com/erro r/delivery&format=pdf [Accessed 12 October 2015]. Tuberculosis Research Centre (TRC). A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre. Int J Tuberc Lung Dis, 1997; 1(6): 509-517. Available at: http://docstore.ingenta.com/cgibin/ds_deliver/1/u/d/ISIS/80321827.1/iuatld/ijtld/1997/00000001/0000000 6/art00007/7754C218C7B4F864141994019730BB7669EB7F1838.pdf?lin k=http://www.ingentaconnect.com/error/delivery&format=pdf [Accessed 12 October 2015]. Tuberculosis Research Centre (TRC). Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle, 1983; 64(2): 73-91. Available at: http://ac.elscdn.com/0041387983900326/1-s2.0-0041387983900326- main.pdf?_tid=9a08b35a-901a-11e4-a802- 00000aab0f27&acdnat=1419940645_afb8443dddffe68a1db9041568483c5 8 [Accessed 12 October 2015]. Uddin SN, Hossain SJ, Huda MN, Rahman MH, Ali ME. Consequence on Treatment of TB Patients Affected by HIV/AIDS A Conceptual Research. Am J Infect Dis, 2006; 2 (4): 210-218. Available at: http://www.researchgate.net/publication/26460063_Consequence_on_Trea tment_of_TB_Patients_Affected_by_HIVAIDS_A_Conceptual_Research [Accessed 12 October 2015]. Van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Eng J Med, 1999; 341: 1174–1179 Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. Rate of Reinfection Tuberculosis after Successful Treatment Is Higher than Rate of New Tuberculosis. Am J Res Crit Care Med, 2005; 171(12): 1430- 1435. Available at: http://www.atsjournals.org/doi/pdf/10.1164/ rccm.200409-1200OC [Accessed 12 October 2015]. Vijay S, Kumar P, Chauhan LS, Vollepore BH, Kizhakkethil UP, Rao SG. Risk factors Associated with Default among New Smear Positive TB Patients Treated Under DOTS in India. PLoS One, 2010; 5(4):e10043. Available at: http://www.plosone.org/article/ fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.001004 3&representation=PDF World Health Organization. Global tuberculosis control. 2010. Available at: http://reliefweb.int/sites/reliefweb.int/files/resources/ F530290AD0279399C12577D8003E9D65-Full_Report.pdf [Accessed 12 October 2015]. World Health Organization. Malaysia TB country profile. 2013. Available at: https://extranet.who.int/sree/Reports?op=Replet&name=/ WHO_HQ_Reports/G2/PROD/EXT/TBCountryProfile&ISO2=my&outty pe=pdf [Accessed 12 October 2015]. World Health Organization. Media Centre. WHO launches new stop TB strategy to fight the global tuberculosis epidemic. 2006. Available at: http://www.who.int/mediacentre/news/releases/2006/pr12/en/ [Accessed 12 October 2015]. Yamagishi F, Toyota M. Research and control of relapse tuberculosis cases. Kekkaku (Tuberculosis), 2009; 84(12): 767-768.
|
| spellingShingle |
The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia
|
| summary |
This study has the intention to determine the median time to develop recurrent tuberculosis [TB] in TB patients attending the Chest Clinic at Hospital Raja Perempuan Zainab II [HRPZ II], Kelantan, Malaysia. Records of 114 recurrent TB patients from 1/1/2003-31/12/2009 were analyzed. Kaplan-Meier analysis was used to examine the median time for recurrence of TB. The overall median time to develop TB recurrence in registered TB recurrent patients was six months [95%CI: 4.58, 7.42] after the previous episode. It was found that recipients of Streptomycin (S), Isoniazid (H) and Rifampicin (R) twice weekly (S2H2R2) drug regimen [p=0.026] or daily HR drug regimen [p=0.049] during the continuation phase took a longer duration to develop recurrent TB than nonrecipients of these medicines by Kaplan-Meier analysis. Moreover, there also existed a significant time difference [P = 0.006] between the defaulters and non-defaulters of treatment to develop recurrent TB. Patients should take the complete course of therapy, to reduce recurrent TB infection. The drug regimens must contain the two most potent first line drugs Isoniazid [H] and Rifampicin [R] during the continuation phase.
|
| title |
The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia
|
| title_full |
The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia
|
| title_fullStr |
The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia
|
| title_full_unstemmed |
The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia
|
| title_short |
The median time to develop recurrent tuberculosis at a tertiary hospital in Kota Bharu, Kelantan, Malaysia
|
| title_sort |
median time to develop recurrent tuberculosis at a tertiary hospital in kota bharu, kelantan, malaysia
|